Gilead Sciences, the Foster City, CA-based biotech company that has a research center in Seattle, said a scientific committee of the European Union adopted a negative opinion of its aztreonam lysine drug. The treatment, an inhalable antibiotic for cystic fibrosis developed by Seattle-based Corus Pharma, was turned down by the FDA last fall. EU regulators said Gilead needs more evidence about long-term benefits, repeated treatments in different age groups, and risk of bacterial resistance, said Thomas Russo, an analyst with Robert W. Baird.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
